Introduction: Spinal cord injury (SCI) results in disruption of synaptic in¯uences on the sympathetic preganglionic neurones. Remodelling of spinal cord circuits takes place in spinal neurones caudal to cord injury. There is an increased vascular alpha-adrenoceptor responsiveness, and peripheral aerent (bladder) stimulation in SCI subjects induces a marked noradrenaline spillover below the level of spinal lesion. These neurophysiological changes possibly contribute to the development of autonomic dysre¯exia, a condition of sympathetic hyper-excitability that develops after cervical, or upper dorsal cord injury with resultant paroxysmal rise in arterial pressure, and provide the scienti®c basis for the use of terazosin, a once-a-day, selective alpha-one adrenergic blocking drug. Objectives: The use of terazosin, a long-acting, alpha 1-selective blocking agent was investigated in SCI patients who developed recurrent symptoms of autonomic dysre¯exia, eg headache, sweating¯ushing of the face together with an increase in the arterial pressure.
Introduction
Autonomic dysre¯exia is an acute syndrome characterised by (1) a sudden increase in blood pressure with compensatory bradycardia, (2) headache, and (3) profuse sweating and vasodilation with skin¯ushing above the level of spinal cord injury. Autonomic dysre¯exia occurs in patients with a spinal cord injury above the greater splanchnic out¯ow, usually above T-6; however, autonomic dysre¯exia has been reported to occur with spinal cord injuries at neurological levels as low as T-8. 1 Proprioceptive and noxious stimuli below the level of injury may induce an episode of autonomic dysre¯exia, and the acute increase in arterial blood pressure may cause seizures, intracerebral haemorrhage, or even death. 2 Although certain events such as distension of the urinary bladder or bowel, acute cystitis, cystoscopy, cystometry, percutaneous nephrolithotomy, extracorporeal shock wave lithotripsy and sexual act 3 may precipitate autonomic dysre¯exia, dyssynergic voiding and irritation of the trigone by an indwelling urinary catheter are the common causes for the occurrence of autonomic dysre¯exia. An algorithm has been proposed for the management of an acute episode of autonomic dysre¯exia after it has occurred. 4 Sublingual administration of nifedipine, a calcium channel blocker, in a dose of ten milligrams secures rapid control of the sudden increase in blood pressure, and is the standard drug therapy for a spinal cord injury patient who has developed the clinical features of autonomic dysre¯exia.
Some spinal cord injury patients tend to develop recurrent episodes of autonomic dysre¯exia. In patients with a predilection for recurrent autonomic dysre¯exia, it is desirable to prevent the occurrence of dysre¯exic episodes. In this subgroup of tetraplegic and paraplegic subjects with a propensity towards recurrent episodes of autonomic dysre¯exia, the precipitating cause for the occurrence of autonomic dysre¯exia may elude precise identi®cation in some. In others, dyssynergic voiding or an indwelling urinary catheter may be the underlying reason. But these patients may not ®nd it easy to change their life style. Therefore, elimination of the precipitating cause for the occurrence of autonomic dysre¯exia may not be feasible. Consequently, these special groups of spinal cord injury patients require round the clock protection against autonomic dysre¯exia on a continual basis.
Spinal cord injury disrupts control of sympathetic preganglionic neurones (SPN) because bulbospinal input has been lost, and the remaining regulation is accomplished by spinal circuits consisting of dorsal root aerent and spinal interneurones. 5 Experimental studies in rats have shown that soon after injury, there is temporary depression of cardiovascular function due to loss of bulbospinal excitatory input. Within a week of spinal cord injury, there is transient atrophy of SPN which could reinforce the sympathetic atonia and hypotension. There is also a loss of dendritic processes on preganglionic neurones, a condition that could render the neurones less receptive to excitatory input. These changes may explain why patients do not manifest autonomic dysre¯exia immediately after the spinal cord injury. In chronic spinal cord-injured rats, one month after cord transection, there is remodelling of the dendritic arbor of preganglionic neurones and the intensity of the reactive gliosis around the preganglionic neurones was diminished. 6 By 30 days after complete transection, the atrophy of SPN had been reversed. This recovery of normal morphology in SPN, and reorganization of synaptic inputs to SPN are consistent with the return of large and sustained excitatory sympathetic responses that cause episodic hypertension (autonomic dysre¯exia) after this time period. In clinical practice also, the episodic hypertensive responses associated with autonomic dysre¯exia undergo a time-dependent increase in magnitude after cord injury. 7 Moreover, sprouting of the central arbour of primary aerent neurones occur by 2 weeks after a spinal cord injury in rats. 8 This exaggerated input to spinal interneurones in deeper laminae of the dorsal horn would also contribute to the development of autonomic dysre¯exia. The current concepts on the neurophysiology of autonomic dysre¯exia in experimental animals, and in spinal cord injury patients are summarised in Appendix 1.
These neurophysiological changes constitute the scienti®c foundation for the pharmacological treatment of recurrent autonomic dysre¯exia with a selective alpha-1 adrenergic blocking agent We report our clinical experience in 24 spinal cord injury patients who developed recurrent episodes of autonomic dysre¯exia and were treated with terazosin, a once-aday, selective alpha-1 adrenergic blocking drug.
Patients and methods
Patients with spinal cord injury who are registered with the Regional Spinal Injuries Centre, Southport were the source of subjects for this study. Any patient who recounted experiencing symptoms of autonomic dysreexia, or who was detected to exhibit recurrent episodes of pounding headaches, sweating, or¯ushing of the face accompanied by an acute increase in the arterial blood pressure, was investigated further as to the possible existence of a predisposing factor for the occurrence of autonomic dysre¯exia. Whenever an obvious precipitating factor for the happening of autonomic dysre¯exia was detected, eg a blocked urinary catheter, appropriate treatment was instituted, viz insertion of a new urinary catheter in this patient. If performance of an invasive procedure was the predisposing factor for the occurrence of autonomic dysre¯exia, an acceptable modification in the performance of such a procedure was adopted. For example, if digital evacuation of the bowels led to the occurrence of a dysre¯exic episode, prior instillation of 2% lignocaine gel into the rectum was the appropriate treatment for the prevention of autonomic dysre¯exia in that particular patient. However, there were situations when it was not possible to identify a predisposing factor for autonomic Twenty-four patients who satis®ed these criteria were the subjects of this report.
Treatment schedule with terazosin
The proposed treatment with terazosin was discussed with the patient and his/her carers. They were informed of the possible side eects of terazosin. If they agreed to the treatment with terazosin, their current medication list was checked. If a patient has been taking a thiazide diuretic say, for swelling of the feet, he or she was advised to stop the diuretic before commencing the treatment with terazosin, as an exaggerated ®rst dose response (vide infra) has been identi®ed in patients pretreated with thiazide diuretics. 9 An initial dose of either one mg in case of adults, or 0.5 mg in case of children, was administered once a day on retiring to bed. This special precaution of administering the ®rst dose of terazosin at bedtime was observed as the ®rst dose may cause collapse due to hypotensive eect within 30 ± 90 min. Patients were warned to lie down if symptoms such as dizziness, or fatigue develop and to remain lying down until these symptoms abate completely. 10 The carers were taught how to recognise the potentially serious adverse events to terazosin. The patients were encouraged to wear a thigh length elastic stocking hopefully to minimise the occurrence of postural hypotension and dizziness. The arterial blood pressure was measured daily as they were sitting up on a chair. Occurrence of the side eects due to terazosin, and symptoms of autonomic dysre¯exia were recorded. If a patient continued to develop symptoms of autonomic dysre¯exia, and the side eects were either absent or only mild, the dose of terazosin was raised at intervals of 3 ± 4 days, the dose increment being 1 milligram in case of adults, and 0.5 milligram in case of children. A maximum permissible dose of terazosin was set at 10 milligrams for an adult patient, and 2 milligrams for a child. The clinical end points were: (1) complete abatement of the symptoms and signs of autonomic dysre¯exia; or (2) occurrence of major side eects which demanded discontinuation of drug therapy, or prevented any further increase in terazosin dosage in order to control the features of autonomic dysre¯exia which were still present After reaching the optimal dose of terazosin, the patients were reviewed either during their follow-up visits to the spinal injuries centre, or during the home visits made by the sta of the spinal injuries centre.
Results
The clinical details of these patients with spinal cord injury are given in Table 1 . There were 18 adult tetraplegics (male: 17 and female: 1) and three male children with ventilator-dependent tetraplegia; there were three male paraplegic patients (level of lesion: T-4 in two patients and T-1 in one patient). No patient exhibited ®rst dose reaction to terazosin. During terazosin therapy, the lowest blood pressure of 78/ 40 mmHg was recorded in a three year old boy who was getting 1 milligram of terazosin nocte. Among the adult tetraplegic subjects, the lowest recording of blood pressure was 85/50 mmHg in a 30 year old male tetraplegic patient with a neurological level of C-5. This patient was taking 2 milligrams of terazosin and he did not develop any side eect such as dizziness. A 39-year old tetraplegic patient has been taking 10 milligrams of terazosin to control the symptoms of autonomic dysre¯exia. He did not develop any side eect to the 10 milligram dosage of terazosin. On one occasion, he was inadvertently given 45 milligrams of terazosin instead of 10 milligrams by his carer, as the new supply of terazosin tablets was of higher strength. He was admitted to the spinal injuries centre as a precautionary measure; he was given 50 grams of activated charcoal by mouth. He did not develop hypotension; his blood pressure remained around 123/ 70 mmHg. He was able to sit up without feeling dizzy the next afternoon, and was discharged home after 18 h of observation.
In contrast, a 54-year old tetraplegic patient (C-7) preferred to discontinue terazosin because he felt dizzy while he sat up. This tetraplegic patient required a dose of 6 milligrams of terazosin in order to abolish completely the symptoms of autonomic dysre¯exia. His blood pressure recording while he was sitting on his chair was 80/52 mmHg. The side eects which were observed in other patients included (i) feelings of tiredness, and (ii) drowsiness; these side eects were mild, self-limiting, and were noticed only during the ®rst week of treatment with terazosin. A 33 year old Treatment of recurrent autonomic dysreflexia in SCI patients with terazosin S Vaidyanathan et al There was considerable variation in the dose of terazosin which was required for complete suppression of the symptoms and signs of autonomic dysre¯exia. The 21 adult patients required doses varying from 1 ± 10 milligrams, whereas the three paediatric patients needed a smaller dose of 1 ± 2 milligrams (Table 1) .
Discussion
Cardiovascular control becomes abnormal, and unstable after cervical and upper dorsal spinal cord injury, as there is either too little or, too much sympathetic activity. Too little sympathetic activity results in low blood pressure and postural hypotension. Too much sympathetic activity leads to autonomic dysre¯exia. The mechanisms mediating autonomic dysre¯exia are not due solely to disinhibition of the spinal re¯exes, and to loss of descending bulbospinal inputs to spinal preganglionic neurones. Reorganization of synapses on spinal sympathetic neurones after cord transection may be crucial for the development of autonomic dysre¯exia. 11 Understanding of the remodelling of spinal cord circuits, which occur after the decentralisation produced by the cord injury, is an essential prerequisite to devising therapeutic regimes either to limit the abnormal synaptic inputs to sympathetic preganglionic neurones which contribute to the occurrence of autonomic dysre¯exia or to counter the peripheral eects of the excessive sympathetic activation.
As a peripheral aerent stimulation causes a marked increase in noradrenaline spillover below the level of lesion in SCI patients 12 and increased vascular alpha-adrenoceptor responsiveness has been demonstrated in tetraplegic patients, 13 we treated these spinal cord injury patients who have been experiencing recurrent episodes of autonomic dysre¯exia with a selective, alpha 1-adrenergic blocking drug. However, both NMDA (N-methyl-D-aspartate) and AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors contribute to spinal viscerosympathetic transmission and initiation of episodic hypertension in conscious spinal rats.
14 Intrathecal administration of NMDA-receptor antagonist AP-5, and AMPA-receptor antagonist NBQX in rats relieve pain syndromes after spinal cord injury, eects that parallel the actions of those antagonists on re¯ex hypertension. 15 Experimental studies in rats demonstrated that nerve ®bres immunoreactive for the neurotransmitter amino acids, glutamate and GABA, provide most of the input to sympathetic preganglionic neurones caudal to a spinal cord transection. 16 Synapses containing glutamate and GABA could provide the anatomical substrate for the exaggerated sympathetic re¯exes and the low sympathetic tone that result from spinal cord injury. Thus modulation of amino acid receptors in the spinal cord by continuous intrathecal administration of a selected drug may provide, yet another therapeutic method, for repressing autonomic dysre¯exia. Indeed, in clinical practice, we observed complete disappearance of recurrent dysre¯exic episodes in a tetraplegic patient following implantation of a programmable pump for continuous intrathecal infusion of baclofen, a GABA B agonist. 17 The mechanisms contributing to the exaggeration of spinal re¯exes are acute loss of bulbospinal inhibition, and reactive reinnervation providing direct or indirect input from spinal and dorsal root aerent neurones to the partially deaerented SPN. As the latter process of reactive reinnervation increases with time after spinal cord injury, 11 it is logical to expect recurrent episodes of autonomic dysre¯exia more frequently in the chronic spinal cord injury patients than in the acutely injured patients. In this clinical series of 24 patients, we observed a considerable time interval between the occurrence of spinal cord injury and their presentation with recurrent autonomic dysre¯exic episodes. Although this time interval was more than 3 years in 19 of the 21 adult patients with spinal cord injury, the time lag was shorter in the three paediatric tetraplegic patients. (Table 1) . It is not known whether the reorganization of synaptic inputs to SPN occurs more rapidly in children than in adults.
One of the patients who developed recurrent episodes of autonomic dysre¯exia had T-4 paraplegia due to viral myelitis (see Table 1 ± patient AM). This case may indicate that a traumatic injury to the spinal cord is not necessary for the remodelling of spinal cord circuits. Thus autonomic dysre¯exia may occur in patients with tetraplegic or paraplegia above T-6 level due to non-traumatic aetiology as well.
Chancellor and associates 18 evaluated terazosin for the treatment of autonomic dysre¯exia in 21 spinal cord injury men and found a signi®cant improvement in the autonomic dysre¯exia severity mean score (before: 2.9; after 3 months of treatment: 1.7) with no signi®cant change in blood pressure. In their 21 men, the degree of head ache did not signi®cantly improve with terazosin. Chancellor and associates 18 however, did not elaborate upon either the selection of cases for treatment with terazosin, or the dosage adjustment in the individual patients. In the present study, all the 18 adult patients were completely relieved of their symptoms inclusive of head ache when the dose of terazosin was titrated according to their individual needs. Occurrence of headache as a symptom of autonomic dysre¯exia, in our opinion, calls for immediate treatment by sublingual administration of the calcium channel blocker, nifedipine. It is important to recognise that terazosin therapy is not the ®rst line of treatment for autonomic dysre¯exia in spinal cord injury patients. If a tetraplegic patient gets dysre¯exia when his urinary catheter is blocked, the acute episode of dysre¯exia should be treated with nifedipine administered sublingually. Further, appropriate modi®cation(s) in the care plan should be implemented without delay to abolish the precipitating factor for the dysre¯exic episodes. In the clinical situation cited above, future occurrence of dysre¯exic episodes can be prevented by avoiding acute distension of the urinary bladder due to blocked catheter by changing the urinary catheter every 4 weeks instead of every 6 weeks. We do not recommend long-term terazosin therapy in such a patient in whom the precipitating cause can be identi®ed, and suitable corrective strategies can be implemented to prevent the recurrence of the predisposing clinical situation. Thus, we reserve treatment with terazosin for the selected patients who manifest recurrent episodes of dysre¯exia and in whom, it is not possible to identify the predisposing cause for the occurrence of autonomic dysre¯exia, or in whom it is not feasible to abolish the precipitating factor for the dysre¯exic episodes because of either social, or personal reasons.
Terazosin has been used more widely in patients with benign hyperplasia of prostate. The side eects of terazosin in the treatment of symptomatic benign prostatic hyperplasia were studied by analysis of seven prospectively designed placebo-controlled trials involving 3080 patients, 1689 of whom received terazosin in doses ranging from 1 ± 20 mg daily for a total of 1282 patient-years of exposure. The most common side eects seen in patients treated with terazosin were dizziness (10.7%), asthenia (7.5%) and peripheral oedema (4.0%). 19 The present study was carried out on 24 tetraplegic/paraplegic patients. Only one of these 24 patients developed a signi®cant side eect of dizziness which required discontinuation of drug treatment No other patient noticed any side eect which interfered with the daily activities of living. Of course, patients with spinal cord injury and patients with benign hyperplasia of prostate represent two dierent population groups and they are not comparable. However, rarity of the occurrence of side eects in the present study is possibly due to the fact that the terazosin doses were adjusted according to the needs of the individual patient All the adult patients were started with a dose of 1 milligram and then the dose was raised in a graded manner depending upon the continued occurrence of dysre¯exic symptoms, the increments being 1 milligram. We did not think that it was appropriate to prescribe a standard dose of say, 4 milligrams of terazosin to all adult patients with spinal cord injury exhibiting autonomic dysre¯exia. By starting with a dose of 1 milligram in adults, and 0.5 milligram of terazosin in case of children and then gradually building up the dose over a period of time, probably the body system was able to adopt itself to the pharmacological actions of terazosin, especially the hypotensive eect of this selective alpha-1 adrenergic blocking drug. Further, by tailoring the terazosin dosage to the individual patients requirements as indicated by the continued presence of dysre¯exic symptoms, we found that patients with spinal cord injury required a varying dose of terazosin, the range being 1 ± 10 milligrams. Further, we took precautions to reduce the occurrence of postural hypotension right from the beginning of terazosin therapy. All the patients were advised to wear elastic stockings (thigh length) to prevent pooling of blood in the lower limbs; some tetraplegic patients wore abdominal binders as well. All the patients received terazosin in the late evening after they were put to bed. There is some evidence that bed-time dosing of alpha-blockers tend to reduce the asthenia and dizziness. 20 Adverse events to terazosin were signi®cantly decreased by administering the drug in the evening to normotensive men with symptomatic prostatism. 21 McKiernan and Lowe 19 observed a statistically signi®cant decreased risk of urinary tract infection and myocardial infarction in the terazosin-treated group among patients with benign hypertrophy of prostate. The ®nding of a decreased incidence of myocardial infarction in the terazosin group may be attributable to the simultaneous favourable eects of terazosin on blood pressure, serum lipids, and left ventricular hypertrophy. 22, 23 The proven bene®ts of terazosin to individuals with benign prostate hypertrophy cannot be extrapolated to patients with spinal cord injury as these represent two distinct populations. However, terazosin therapy results in improved voiding with a decreased residual urine in spinal cord injury patients as well. Holding large amount of residual urine is one of the predisposing factors for the occurrence of urinary tract infection in tetraplegic and paraplegic patients. Improved bladder emptying along with a decrease in the amount of residual urine as a consequence of terazosin therapy is likely to result in a diminished incidence in urinary infection in spinal cord injury patients taking terazosin on a long-term basis.
Further, spinal cord injury patients with autonomic dysfunction are reported to have an increased risk for cardiovascular morbidity and mortality. 24 Cardiovascular diseases are the most frequent cause of death among persons with spinal cord injury, and these diseases are reported to occur prematurely in the disabled compared to the able-bodied population. 25 If terazosin therapy results in favourable changes in the lipid pro®le of patients with spinal cord injury, such a drug-induced decrease in the blood cholesterol level may be yet another advantage of terazosin therapy in the spinal cord injury patients. However, these hypotheses on the eects of terazosin, viz (i) decreasing the incidence of urinary infection and (ii) diminishing the morbidity due to cardiovascular diseases in patients with spinal cord injury, need to be tested by carrying out controlled clinical trials in the spinal cord injury population.
With improved understanding of the neurobiology of the traumatised spinal cord, a molecular biological approach may become feasible in future, for the modulation of the remodelling processes occurring in Treatment of recurrent autonomic dysreflexia in SCI patients with terazosin S Vaidyanathan et al the spinal cord caudal to the level of injury, as sprouting of primary aerent neurones and spinal interneurones with formation of new synapses on spinal preganglionic neurones may be crucial for the development of autonomic dysre¯exia. With the molecular cloning of the receptors for excitatory neurotransmitters, and application of antisense oligonucleotides technology, it may be possible to block or alter the expression of the genes for the speci®c excitatory receptor subtypes. 26 Therefore, in the next century, therapeutic interventions may be directed at the genes themselves, in an attempt to treat disorders that involve the exaggerated sympathetic re¯exes, such as autonomic dysre¯exia.
